PFE - Pfizer Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
37.35
-0.31 (-0.81%)
As of 3:57PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close37.66
Open37.45
Bid37.39 x 800
Ask37.40 x 28000
Day's Range37.31 - 37.60
52 Week Range32.32 - 39.43
Volume13,173,678
Avg. Volume20,500,949
Market Cap218.511B
Beta0.92
PE Ratio (TTM)10.38
EPS (TTM)3.60
Earnings DateJul 31, 2018
Forward Dividend & Yield1.36 (3.66%)
Ex-Dividend Date2018-08-02
1y Target Est39.80
Trade prices are not sourced from all markets
  • MarketWatch6 hours ago

    AbbVie shares drop 5.5% after short seller Citron calls it 'next great drug short'

    AbbVie Inc. (ABBV) shares dropped 5.5% in heavy Thursday morning trade after short seller Citron Research described the company as "the next great drug short" in a tweet and said it planned to release reports about the company. The Citron tweet came the day after Food and Drug Administration Commissioner Scott Gottlieb put out a plan to encourage the development and uptake of lower-priced biosimilar drugs, accusing large drugmakers in a speech of stymying the competition. The short seller also predicted that AbbVie shares, which closed at $94.40 on Wednesday, would drop to $60.

  • Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study
    Zacks6 hours ago

    Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study

    Pfizer (PFE) and Eli Lilly (LLY) announce that their investigational pain candidate, tanezumab, significantly reduces pain in osteoarthritis patients.

  • Better Buy: Novavax, Inc. vs. Pfizer
    Motley Fool8 hours ago

    Better Buy: Novavax, Inc. vs. Pfizer

    Novavax and Pfizer have been chronic underachievers, but their stocks may soon perk up. Here's a look at which stock is the better buy right now.

  • Reuters9 hours ago

    Trump thanks Novartis, Pfizer for not raising drug prices

    U.S. President Donald Trump thanked two major drug companies on Thursday for not raising their prices and said his administration was working toward substantially cutting prescription-drug prices. "Thank you to Novartis for not increasing your prices on prescription drugs. Earlier this month Trump was able to persuade Pfizer CEO Ian Read to defer the company's planned price hikes, explaining in a call the company had complicated the administration's drug pricing plans.

  • Reuters9 hours ago

    Trump thanks Novartis, Pfizer for not raising drug prices

    U.S. President Donald Trump thanked two major drug companies on Thursday for not raising their prices and said his administration was working toward substantially cutting prescription-drug prices. "Thank you to Novartis for not increasing your prices on prescription drugs. Earlier this month Trump was able to persuade Pfizer CEO Ian Read to defer the company's planned price hikes, explaining in a call the company had complicated the administration's drug pricing plans.

  • The Wall Street Journal20 hours ago

    [$$] Novartis Won’t Raise U.S. Drug Prices This Year

    Novartis AG won’t increase its U.S. drug prices for the rest of 2018, the Switzerland-based drugmaker said Wednesday, days after Pfizer Inc. took a similar step following criticism from President Donald Trump. In an interview, Novartis Chief Executive Vas Narasimhan said the company would evaluate its strategy for 2019 when it has more clarity on the pricing environment. Last week, Pfizer said it would defer some recent drug-price increases, reversing course after Mr. Trump criticized the company for its plans to raise the prices of more than 40 drugs.

  • MarketWatchyesterday

    Pfizer, Eli Lilly non-opioid pain drug nears finish line

    A new non-opioid drug for osteoarthritis pain being developed by Pfizer Inc. (PFE) and Eli Lilly & Co. (LLY) had positive early results in a phase 3 clinical trial, the companies announced on Wednesday. Patients who received two doses of the drug had a statistically significant improvement in pain, physical function and their own assessment of their osteoarthritis, relative to patients on the placebo. More information about progressive osteoarthritis seen in patients is still needed, though, said EvercoreISI analyst Umer Raffat, and the companies in particular "likely [need] longer follow up before being more definitive" about tanezumab's safety.

  • TheStreet.comyesterday

    5 Big Biotech Stories to Watch

    President Trump's attack on large pharma companies over drug prices might have grabbed headlines recently, but that shouldn't distract from the firms and drugs that have been driving change and innovation in the biotech industry. Here's a rundown of some of the news from small to large companies in the past few weeks that could have a big impact on the biotechnology and pharmaceutical sectors. 1. Biogen's Alzheimer's drug trial results show promise Curing Alzheimer's disease has frustrated the healthcare industry for years after numerous failed attempts have been made to find a treatment, but Biogen Inc.

  • Novartis hints at 2018 outlook hike despite drug price freeze
    Reutersyesterday

    Novartis hints at 2018 outlook hike despite drug price freeze

    Novartis (NOVN.S) may ratchet up its 2018 sales outlook, its finance chief said on Wednesday, despite halting planned U.S. drug price hikes amid pressure on the industry from President Donald Trump's administration over the high cost of medicines. Shares in the Swiss drugmaker, whose decision to freeze prices this year in the world's largest drug market was mirrored by Pfizer (PFE.N), closed 2.5 percent higher in Zurich after the firm beat forecasts with second-quarter results.

  • Reutersyesterday

    Pfizer-Lilly pain drug meets late-stage trial goals

    The treatment, tanezumab, belongs to an investigational category of pain medications that target nerve growth factor, a protein involved in the growth of nerve cells, and is also being evaluated to treat chronic lower back and cancer pain. U.S. regulators in 2015 lifted a hold on trials of medicines targeting the protein due to concerns they could worsen osteoarthritis in a small percentage of patients. Pfizer's shares were marginally up at $37.79 in premarket trade.

  • Reutersyesterday

    Pfizer-Lilly pain drug meets late-stage trial goals

    An experimental osteoarthritis drug developed by Pfizer Inc and Eli Lilly and Co achieved its main goal of lowering pain in a late stage trial, the companies said on Wednesday, potentially offering a safer alternative to opioids. The treatment, tanezumab, belongs to an investigational category of pain medications that target nerve growth factor, a protein involved in the growth of nerve cells, and is also being evaluated to treat chronic lower back and cancer pain. U.S. regulators in 2015 lifted a hold on trials of medicines targeting the protein due to concerns they could worsen osteoarthritis in a small percentage of patients.

  • Benzingayesterday

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Pfizer Inc. (NYSE: PFE ) stock was trading slightly ...

  • Reutersyesterday

    Hikma raising injectable opioids output to help ease shortage at U.S. hospitals

    London-listed pharmaceutical group Hikma said on Wednesday it was increasing its supply of hydromorphone to U.S. hospitals to help ease a shortage of injectable opioids used to treat patients. Injectable opioid painkillers, which hospitals use to manage pain after operations and in terminal illness, have been in short supply for more than a year largely due to production problems at Pfizer, the biggest supplier of the drugs. Pfizer has said it is making progress on its recovery plan, but it estimates that the supply of some of its injectables will not be fully restored until later this year or in 2019.

  • Reutersyesterday

    Novartis joins Pfizer in halting U.S. drug price hikes

    Novartis expects to hit the top of its 2018 sales guidance after a strong second quarter, the CEO said, despite joining Pfizer in freezing its U.S. drug prices for the rest of the year following pressure from President Donald Trump. Chief Executive Vas Narasimhan said Novartis would likely easily achieve mid-single digit percentage sales growth for 2018, on rising demand for psoriasis-and-arthritis drug Cosentyx and robust sales of heart-failure medicine Entresto. "We would expect to see, assuming continued momentum like we're seeing now, to be at the high end of that range," Narasimhan said, adding that this would come without price hikes as Novartis keeps the lid on medicine costs under pressure from U.S. lawmakers and Trump.

  • Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain
    Business Wireyesterday

    Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain

    Pfizer Inc.(PFE) and Eli Lilly and Company (LLY) today announced that a 16-week Phase 3 study in patients with osteoarthritis (OA) pain evaluating subcutaneous administration of tanezumab, an investigational humanized monoclonal antibody, met all three co-primary endpoints. The study demonstrated that patients who received two doses of tanezumab separated by eight weeks experienced a statistically significant improvement in pain, physical function and the patients’ overall assessment of their OA, compared to those receiving placebo. Tanezumab is part of an investigational class of pain medications known as nerve growth factor (NGF) inhibitors and in addition to OA pain, is being evaluated for chronic low back pain (CLBP) and cancer pain (due to bone metastases).

  • Novartis Joins Pfizer in Holding Line on Drug Prices in U.S.
    Bloomberg2 days ago

    Novartis Joins Pfizer in Holding Line on Drug Prices in U.S.

    Swiss drugmaker Novartis AG is holding the line on U.S. prices this year as an attack from President Donald Trump led rival Pfizer Inc. to delay planned increases for some medicines. Novartis has voluntarily pulled back on increasing prices in the U.S., Chief Executive Officer Vas Narasimhan said on a call Wednesday.

  • Novartis CEO Says Drugmaker Won't Raise U.S. Prices This Year
    Bloomberg2 days ago

    Novartis CEO Says Drugmaker Won't Raise U.S. Prices This Year

    Swiss drugmaker Novartis AG is holding the line on prices in the U.S. this year, following a move by rival Pfizer Inc. to delay planned increases for some medicines after President Donald Trump launched an attack on the U.S. pharma giant. Novartis has voluntarily pulled back on increasing prices in the U.S., Chief Executive Officer Vas Narasimhan said on a call Wednesday with journalists. Pfizer last week agreed to defer planned price increases for certain drugs a day after Trump targeted Pfizer over reported plans to implement a series of price increases, criticizing the move on Twitter and briefly rattling its shares.

  • Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III
    Zacks2 days ago

    Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III

    Pfizer (PFE) initiates phase III program on a gene therapy treatment, fidanacogene elaparvovec, for patients with hemophilia B.

  • Investopedia2 days ago

    TD Ameritrade: Setting Time Target Best Way for Investors to Ignore Noise

    Geopolitical tensions are rising, and trade disagreements are increasing, leaving investors confused as to how to react to the daily headlines emanating out of Washington and Wall Street. A better option, one advocated by TD Ameritrade's chief market strategist J.J. Kinahan, is to set a time target on the investments in a portfolio and stick to it. "A lot of people set price targets, but they don't do a good enough job setting a time target," said Kinahan in an interview with Investopedia.

  • CNBC2 days ago

    Johnson & Johnson CEO defends drug prices, calls for changes in how medical costs are covered

    Johnson & Johnson CEO Alex Gorsky called for changes in the way prescription drugs are paid for but stopped short of saying pharmaceutical companies need to lower the prices they charge.

  • Investopedia2 days ago

    How Johnson & Johnson Became A Household Name

    New Brunswick, N.J.-based Johnson & Johnson (NYSE:  JNJ) is probably most famous as the parent company of multiple household products that double as household names. If you’ve ever bandaged a wound, rinsed your mouth, applied lotion, sanitized your hands, battled a headache, substituted sugar or treated heartburn, chances are excellent that you did so courtesy of Johnson & Johnson’s research and development. To quote company Chairman and CEO Alex Gorsky, “approximately 70% of our sales come from products with the number one or number two global market share position.” Johnson & Johnson boasts no fewer than 275 subsidiary companies, up from 250 three years ago.

  • CNBC3 days ago

    Increasing drug prices despite public scrutiny 'makes absolutely no sense,' says analyst

    Some drug companies continue to raise prices, despite mounting public scrutiny and pressure from the president. Pfizer raised the price of more than 40 medications at the beginning of July. "The pharmaceutical industry is very much addicted to price inflation in terms of growth," said analyst Elliot Wilbur.

  • Pfizer begins late-stage testing of Spark's hemophilia B gene therapy
    American City Business Journals3 days ago

    Pfizer begins late-stage testing of Spark's hemophilia B gene therapy

    The two companies, which said a licensing deal in 2014, have completed the transfer of the therapy's development from Spark to Pfizer.

  • UAB researchers make big discovery on diabetes research
    American City Business Journals3 days ago

    UAB researchers make big discovery on diabetes research

    UAB researchers have made a significant discovery in diabetes research – one that could reduce the skyrocketing costs of treatment.